ResearcherUniversidade do PortoActive in the last 2 years
Cristina P. R. Xavier
Matched on ORCID iD 0000-0002-4613-1917; OpenAlex author ID A5047567407. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 6
- Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications. Last author DOI 10.1016/j.pan.2026.10.025↗
- Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00280-024-04712-1↗
- Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems. Co-author DOI 10.1016/j.semcancer.2024.09.002↗
- Fibroblasts in pancreatic cancer: molecular and clinical perspectives. First author DOI 10.1016/j.molmed.2023.03.002↗
- Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabin… Co-author DOI 10.1016/j.canlet.2020.11.013↗
- Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ph14030280↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- M. Helena Vasconcelos · 5 shared papers, 2021–2026 · strength 1.22
- Paper Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications. DOI 10.1016/j.pan.2026.10.025↗
- Paper Fibroblasts in pancreatic cancer: molecular and clinical perspectives. DOI 10.1016/j.molmed.2023.03.002↗
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1↗
- Elisa Giovannetti · 3 shared papers, 2023–2024 · strength 0.67
- Paper Fibroblasts in pancreatic cancer: molecular and clinical perspectives. DOI 10.1016/j.molmed.2023.03.002↗
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1↗
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Rita Rebelo · 3 shared papers, 2021–2024 · strength 0.63
- Paper Fibroblasts in pancreatic cancer: molecular and clinical perspectives. DOI 10.1016/j.molmed.2023.03.002↗
- Paper Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model sys… DOI 10.1016/j.semcancer.2024.09.002↗
- Paper Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ph14030280↗
- Rúben Rodrigues · 1 shared paper, 2026 · strength 0.43
- Sofia Martins Sousa · 1 shared paper, 2024 · strength 0.22
- Luca Morelli · 1 shared paper, 2024 · strength 0.22
- Amir Avan · 1 shared paper, 2024 · strength 0.22
- Benoît Immordino · 1 shared paper, 2024 · strength 0.19
- Macarena Perán · 1 shared paper, 2024 · strength 0.19
- Manoj Amrutkar · 1 shared paper, 2024 · strength 0.19
- Naomi Walsh · 1 shared paper, 2024 · strength 0.19
- Alessandro Gregori · 1 shared paper, 2024 · strength 0.19
- Belén Toledo · 1 shared paper, 2024 · strength 0.19
- Giulia Lencioni · 1 shared paper, 2024 · strength 0.19
- Justo Pastor Castano · 1 shared paper, 2024 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.